I work in the Policy, Evidence and Influencing team at Breast Cancer Now.
A key area of our work is improving access to drugs. We ensure decision-makers hear the views of patients about the importance of new, clinically-effective drugs reaching people swiftly.
The National Institute of Health and Care Excellence (NICE) wants to hear our views on a new breast cancer treatment.
- Atezolizumab (also known as Tecentriq) in combination with chemotherapy for neoadjuvant (before surgery) treatment of triple negative early breast cancer.
If you have experience of taking this treatment combination before surgery, you could help shape our input into NICE’s assessment on whether this treatment will be available on the NHS.